Current Approaches for Predicting a Lack of Response to Anti-EGFR Therapy in KRAS Wild-Type Patients
Figure 1
Downstream signaling proteins of EGFR: (a) KRAS, (b) NRAS, (c) BRAF, and (d) PIK3CA. The most frequent activating mutation sites are shown as red spheres.
